BIOATLA, INC. Operating Cash Flow
BIOATLA, INC. (BCAB) reported Operating Cash Flow of -$5.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- BIOATLA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$419.00K.
- BIOATLA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.27M.
- BIOATLA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.92M.
- BIOATLA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.88M.
- BIOATLA, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$48.20M.
- BIOATLA, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$71.94M.
- BIOATLA, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$104.02M.
- BIOATLA, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$90.42M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.69M 10-Q · filed 2026-08-13 | -$13.60M derived: sum of 3 quarters · filed 2026-08-13 | -$23.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$5.27M 10-Q · filed 2026-05-15 | -$13.18M derived: sum of 2 quarters · filed 2026-05-15 | -$23.06M derived: sum of 3 quarters · filed 2026-05-15 | -$37.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$17.80M derived: sum of 2 quarters · filed 2026-03-31 | -$31.92M derived: sum of 3 quarters · filed 2026-08-13 | -$48.20M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$9.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$24.00M derived: sum of 2 quarters · filed 2026-08-13 | -$40.29M 10-Q · filed 2025-11-13 | -$57.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$14.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$30.41M 10-Q · filed 2026-08-13 | -$47.19M derived: sum of 3 quarters · filed 2026-08-13 | -$52.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$16.29M 10-Q · filed 2026-05-15 | -$33.07M derived: sum of 2 quarters · filed 2026-05-15 | -$38.20M derived: sum of 3 quarters · filed 2026-05-15 | -$57.40M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$16.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$21.91M derived: sum of 2 quarters · filed 2026-03-31 | -$41.11M derived: sum of 3 quarters · filed 2026-03-31 | -$71.94M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$5.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$24.32M derived: sum of 2 quarters · filed 2025-11-13 | -$55.15M 10-Q · filed 2025-11-13 | -$85.08M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$19.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$50.02M 10-Q · filed 2025-08-07 | -$79.94M derived: sum of 3 quarters · filed 2025-08-07 | -$107.29M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$30.83M 10-Q · filed 2025-05-06 | -$60.75M derived: sum of 2 quarters · filed 2025-05-06 | -$88.09M derived: sum of 3 quarters · filed 2025-05-06 | -$112.19M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$29.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$57.27M derived: sum of 2 quarters · filed 2025-03-28 | -$81.36M derived: sum of 3 quarters · filed 2025-03-28 | -$104.02M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$27.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$51.44M derived: sum of 2 quarters · filed 2024-11-07 | -$74.09M 10-Q · filed 2024-11-07 | -$98.44M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$24.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$46.75M 10-Q · filed 2024-08-08 | -$71.09M derived: sum of 3 quarters · filed 2024-08-08 | -$95.11M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$22.65M 10-Q · filed 2024-05-14 | -$47.00M derived: sum of 2 quarters · filed 2024-05-14 | -$71.02M derived: sum of 3 quarters · filed 2024-05-14 | -$87.94M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$24.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$48.36M derived: sum of 2 quarters · filed 2024-03-26 | -$65.28M derived: sum of 3 quarters · filed 2024-03-26 | -$90.42M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$24.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$40.94M derived: sum of 2 quarters · filed 2023-11-07 | -$66.07M 10-Q · filed 2023-11-07 | -$87.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$16.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$42.06M 10-Q · filed 2023-08-01 | -$63.01M derived: sum of 3 quarters · filed 2023-08-01 | -$75.73M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$25.14M 10-Q · filed 2023-05-11 | -$46.09M derived: sum of 2 quarters · filed 2023-05-11 | -$58.81M derived: sum of 3 quarters · filed 2023-05-11 | -$72.36M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$20.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$33.67M derived: sum of 2 quarters · filed 2023-03-23 | -$47.22M derived: sum of 3 quarters · filed 2023-03-23 | -$62.21M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$12.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$26.27M derived: sum of 2 quarters · filed 2022-11-04 | -$41.27M 10-Q · filed 2022-11-04 | -$55.27M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | -$13.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$28.54M 10-Q · filed 2022-08-09 | -$42.55M derived: sum of 3 quarters · filed 2022-08-09 | -$58.01M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$14.99M 10-Q · filed 2022-05-05 | -$29.00M derived: sum of 2 quarters · filed 2022-05-05 | -$44.46M derived: sum of 3 quarters · filed 2022-05-05 | -$47.51M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$14.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$29.47M derived: sum of 2 quarters · filed 2022-02-28 | -$32.52M derived: sum of 3 quarters · filed 2022-02-28 | -$36.33M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$15.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$18.51M derived: sum of 2 quarters · filed 2021-11-15 | -$22.33M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$6.87M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$3.81M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$9.64M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |